AU2021246973A1 - 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting - Google Patents

1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting Download PDF

Info

Publication number
AU2021246973A1
AU2021246973A1 AU2021246973A AU2021246973A AU2021246973A1 AU 2021246973 A1 AU2021246973 A1 AU 2021246973A1 AU 2021246973 A AU2021246973 A AU 2021246973A AU 2021246973 A AU2021246973 A AU 2021246973A AU 2021246973 A1 AU2021246973 A1 AU 2021246973A1
Authority
AU
Australia
Prior art keywords
piperazine
dimethylphenylsulfanyl
phenyl
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021246973A
Other languages
English (en)
Inventor
Michael Cronquist CHRISTENSEN
Ioana Florea
Carlos Forray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2021246973A1 publication Critical patent/AU2021246973A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021246973A 2020-04-03 2021-04-02 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting Pending AU2021246973A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20167895 2020-04-03
EP20167895.0 2020-04-03
EP20185247 2020-07-10
EP20185247.2 2020-07-10
PCT/IB2021/000207 WO2021198778A1 (en) 2020-04-03 2021-04-02 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting

Publications (1)

Publication Number Publication Date
AU2021246973A1 true AU2021246973A1 (en) 2022-11-03

Family

ID=75825817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021246973A Pending AU2021246973A1 (en) 2020-04-03 2021-04-02 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting

Country Status (5)

Country Link
JP (1) JP2023520016A (ko)
KR (1) KR20220163997A (ko)
AU (1) AU2021246973A1 (ko)
CL (1) CL2022002698A1 (ko)
WO (1) WO2021198778A1 (ko)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN101472906B (zh) 2006-06-16 2012-04-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات

Also Published As

Publication number Publication date
KR20220163997A (ko) 2022-12-12
JP2023520016A (ja) 2023-05-15
WO2021198778A1 (en) 2021-10-07
CL2022002698A1 (es) 2023-03-31

Similar Documents

Publication Publication Date Title
Bennett et al. Suvorexant, a dual orexin receptor antagonist for the management of insomnia
De Vries et al. Guide to good prescribing: a practical manual
US10322119B2 (en) Use of pridopidine for treating Huntington's disease
Haney et al. Marijuana withdrawal in humans: effects of oral THC or divalproex
Morgan et al. Normalizing effects of modafinil on sleep in chronic cocaine users
Vermeeren et al. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females
Solomons et al. Substance abuse: case management and dental treatment: clinical review
Pirtle et al. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study
Lofwall et al. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults.
US11090297B2 (en) Pridopidine for treating huntington's disease
US20130274289A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
Castle et al. Physical Health and Schizophrenia
Shiigi et al. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates
Haney et al. Smoked cocaine discrimination in humans: effects of gabapentin
JP2017031159A (ja) 統合失調症を処置するための環状アミド誘導体の使用の方法
Zacny Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers
TWI784220B (zh) 腦性麻痺運動障礙之治療方法
AU2021246973A1 (en) 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
Kasckow et al. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the BEHAVE-AD and CGI rating scales
Williamson et al. Drug-dependent, alcohol-dependent, and mental patients: clinical study of oral surgery procedures
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
US20230059709A1 (en) Treatment of fragile x syndrome with cannabidiol
WO2024107681A1 (en) Methods of switching neuropsychiatric medications using ulotaront
Shanbhag et al. Pharmacology: Prep Manual for Undergraduates E-book
Singhal et al. Who is pushing patients to death trap by improper use of codeine? Time now to reorient physicians or ban the use of codeine!